Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can allergy drugs help kids tolerate peanut and more?

NCT ID NCT03679676

Completed Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the drugs omalizumab (Xolair) or dupilumab (Dupixent) to oral immunotherapy (OIT) helps people with multiple food allergies tolerate more allergens. 130 participants aged 4 to 55 with allergies to peanut plus one or two other foods were enrolled. The goal was to see if these biologics improve the success of passing a food challenge to peanut and other allergens.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
omalizumab (Xolair) and dupilumab (Dupixent)
What this could lead to
If successful, this could lead to a safer and more effective way to treat multiple food allergies at once, reducing the risk of severe allergic reactions.
What could go wrong
This is a Phase 2 trial with a moderate number of participants, so results may not apply to everyone. The biologics can have side effects, and the treatment may not work for all allergens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic disease food allergy hypersensitivity reaction disease Peanut Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOOD ALLERGY HYPERSENSITIVITY HYPERSENSITIVITY, FOOD PEANUT ALLERGY PEANUT HYPERSENSITIVITY

Contacts and locations

Locations

  • Sean N. Parker Center for Allergy & Asthma Research at Stanford University

    Palo Alto, California, 94304, United States

  • University of California Los Angeles (UCLA)

    Los Angeles, California, 90095, United States

  • University of California San Diego (UCSD)

    San Diego, California, 92123, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.